secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2024-10-02T23:59:59+00:00
Accession:  0001601830-24-000165
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears IND for Recursion's REC-1245, a first-in-class RBM39 degrader for solid tumors/lymphoma
--------------------------------------------------------------------------------

- FDA cleared IND for REC-1245, a potential first-in-class RBM39 degrader for biomarker-enriched solid tumors and lymphoma.
- Phase 1/2 trial to start Q4 2024 evaluating safety, tolerability, PK/PD, and monotherapy efficacy.
- Target identified via Recursion's AI platform; program advanced from target to IND in under 18 months.
- Initially addressable population estimated at >100,000 patients in the US and EU5.
- Preclinical data show RBM39 degradation induces splicing defects downregulating DNA Damage Response networks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000165/0001601830-24-000165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000165/rxrx-20241002.htm
  HTML page:      https://secwatch.observer/filing/0001601830-24-000165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer